Goodwin Procter advised Prime Medicine™ on the deal. Prime Medicine™ announced its launch and funding rounds totaling $315 million. Prime Medicine is a biotechnology company founded to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced the closing of a $105 million private financing round which was led by BVF Partners...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised GeneWerk on the deal. GeneWerk announced its merger with Protagen Protein Services. GeneWerk, an Ampersand portfolio company, is a cell and gene therapy testing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised CIC Capital Deutschland GmbH and Crédit Mutuel Innovation on the deal. ADVITOS GmbH, a Munich-based medical technology company, announced the completion of a EUR...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Matheson advised Circle on the deal. Arthur Cox and Greenberg Traurig advised Concord Acquisition Corp. Circle announced its definitive business combination agreement with Concord...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Origin.Bio on the deal. Origin.Bio announced its US$15 million Series Seed Financing Round, led by EQT Ventures with participation from existing investor BlueYard...
You must be a Standard 1 Year member to access this content.
Goldman Sachs & Co. LLC acted as exclusive financial advisor, and Davis Polk & Wardwell LLP and Taft Stettinius & Hollister LLP acted as legal advisors...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised TA Associates on the deal. TA Associates announced its definitive agreement with Genstar Capital to merge their portfolio companies, Compusoft and 2020 Technologies,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Cerevel Therapeutics on the deal. Cerevel Therapeutics (Nasdaq: CERE) announced its underwritten public offering of 14,000,000 shares of common stock at a public offering...
You must be a Standard 1 Year member to access this content.
IN BRIEF: Gide Loyrette Nouel, Goodwin Procter, advised on the matter. Gide Loyrette Nouel advised Mnemo Therapeutics with a team including David-James Sebag (Picture – Corporate...
You must be a Standard 1 Year member to access this content.
IN BRIEF: Agilys Avocats, Allen & Overy, Cornet Vincent Ségurel, Goodwin Procter, advised on the matter. Agilys Avocats advised Unigrains with a team including Baptiste Bellone...
You must be a Standard 1 Year member to access this content.
IN BRIEF: Freshfields Bruckhaus Deringer LLP, Gide Loyrette Nouel, Goodwin Procter, Latham & Watkins, Paul Hastings LLP, Weil, Gotshal & Manges, advised on the matter. Freshfields...
You must be a Standard 1 Year member to access this content.
